Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Development and testing of the Oncology Patients' Perceptions of the Quality of Nursing Care Scale.

Autor: Radwin L (AUTHOR), Alster K (AUTHOR), Rubin KM (AUTHOR)

Publikováno v: Oncology Nursing Forum. Mar/Apr2003, Vol. 30 Issue 2, p283-290. 8p.

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0.

Autor: Pavlick AC; Weill Cornell Medicine, New York, New York, USA acp9008@med.cornell.edu., Ariyan CE; Department of Surgery Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Buchbinder EI; Melanoma Disease Center, Dana Farber Cancer Institute, Boston, Massachusetts, USA., Davar D; Hillman Cancer Center, University of Pittsburg Medical Center, Pittsburgh, Pennsylvania, USA., Gibney GT; Lombardi Comprehensive Cancer Center, MedStar Georgetown University Hospital, Washington, District of Columbia, USA., Hamid O; The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles, California, USA., Hieken TJ; Department of Surgery and Comprehensive Cancer Center, Mayo Clinic, Rochester, Minnesota, USA., Izar B; Department of Medicine, Division of Hematology/Oncology, Columbia University Medical Center, New York, New York, USA., Johnson DB; Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA., Kulkarni RP; Departments of Dermatology, Oncological Sciences, Biomedical Engineering, and Center for Cancer Early Detection Advanced Research, Knight Cancer Institute, OHSU, Portland, Oregon, USA.; Operative Care Division, VA Portland Health Care System (VAPORHCS), Portland, Oregon, USA., Luke JJ; Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA., Mitchell TC; Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA., Mooradian MJ; Cancer Center, Massachusetts General Hospital, Boston, Massachusetts, USA., Rubin KM; Cancer Center, Massachusetts General Hospital, Boston, Massachusetts, USA., Salama AK; Department of Medicine, Division of Medical Oncology, Duke University, Durham, Carolina, USA., Shirai K; Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA., Taube JM; Department of Dermatology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Tawbi HA; Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Tolley JK; Patient Advocate, Melanoma Research Alliance, Washington, DC, USA., Valdueza C; Cutaneous Oncology Program, Weill Cornell Medicine, New York, New York, USA., Weiss SA; Department of Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA., Wong MK; Patient Advocate, Melanoma Research Alliance, Washington, DC, USA., Sullivan RJ; Cancer Center, Massachusetts General Hospital, Boston, Massachusetts, USA.

Publikováno v: Journal for immunotherapy of cancer [J Immunother Cancer] 2023 Oct; Vol. 11 (10).

Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti-PD-1 Monotherapy.

Autor: Bai X; Department of Melanoma and Sarcoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Peking University Cancer Hospital and Institute, Beijing, China.; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts., Hu J; Department of Data Sciences (Division of Biostatistics), Dana-Farber Cancer Institute, Boston, Massachusetts., Betof Warner A; Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York., Quach HT; Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee., Cann CG; Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee., Zhang MZ; Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee., Si L; Department of Melanoma and Sarcoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Peking University Cancer Hospital and Institute, Beijing, China., Tang B; Department of Melanoma and Sarcoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Peking University Cancer Hospital and Institute, Beijing, China., Cui C; Department of Melanoma and Sarcoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Peking University Cancer Hospital and Institute, Beijing, China., Yang X; Department of Melanoma and Sarcoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Peking University Cancer Hospital and Institute, Beijing, China.; Department of Medical Oncology, Shanxi Bethune Hospital, Shanxi, China., Wei X; Department of Melanoma and Sarcoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Peking University Cancer Hospital and Institute, Beijing, China., Pallan L; Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney, Australia., Harvey C; Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney, Australia., Manos MP; Center for Immune-Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Ouyang O; Center for Immune-Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Kim MS, Kasumova G, Cohen JV; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts., Lawrence DP; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts., Freedman C; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts., Fadden RM; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts., Rubin KM; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts., Sharova T; Department of Surgical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts., Frederick DT; Department of Surgical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts., Flaherty KT; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.; Senior authors at each site., Rahma OE; Center for Immune-Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.; Senior authors at each site., Long GV; Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney, Australia.; Senior authors at each site., Menzies AM; Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney, Australia.; Senior authors at each site., Guo J; Department of Melanoma and Sarcoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Peking University Cancer Hospital and Institute, Beijing, China.; Senior authors at each site., Shoushtari AN; Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York.; Senior authors at each site., Johnson DB; Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.; Senior authors at each site., Sullivan RJ; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.; Senior authors at each site., Boland GM; Department of Surgical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. gmboland@partners.org.; Senior authors at each site.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2021 Nov 01; Vol. 27 (21), pp. 5993-6000. Date of Electronic Publication: 2021 Aug 10.

Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors.

Autor: Guidon AC; Harvard Medical School, Boston, Massachusetts, USA AGUIDON@PARTNERS.ORG kreynolds7@partners.org.; Division of Neuromuscular Medicine, Department of Neurology, Massachusetts General Hospital, Boston, MA, USA., Burton LB; Harvard Medical School, Boston, Massachusetts, USA.; Division of Neuromuscular Medicine, Department of Neurology, Massachusetts General Hospital, Boston, MA, USA., Chwalisz BK; Harvard Medical School, Boston, Massachusetts, USA.; Division of Neuroimmunology and Neuroinfectious Disease, Massachusetts General Hospital, Boston, Massachusetts, USA.; Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Boston, MA, USA., Hillis J; Harvard Medical School, Boston, Massachusetts, USA.; Division of Neuroimmunology and Neuroinfectious Disease, Massachusetts General Hospital, Boston, Massachusetts, USA., Schaller TH; Project Data Sphere, Cary, North Carolina, USA., Amato AA; Harvard Medical School, Boston, Massachusetts, USA.; Division of Neuromuscular Medicine, Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA., Betof Warner A; Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Brastianos PK; Harvard Medical School, Boston, Massachusetts, USA.; Department of Medicine, Massachusetts General Hospital, Boston, MA, USA., Cho TA; Department of Neurology, The University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA., Clardy SL; Department of Neurology, University of Utah, Salt Lake CIty, UT, USA., Cohen JV; Division of Oncology, Department of Medicine, University of Pennsylvania, PA, USA., Dietrich J; Harvard Medical School, Boston, Massachusetts, USA.; Division of Neuro-Oncology, Department of Neurology, Massachusetts General Hospital, Boston, MA, USA., Dougan M; Harvard Medical School, Boston, Massachusetts, USA.; Department of Medicine, Division of Gastroenterology, Massachusetts General Hospital, Boston, Massachusetts, USA., Doughty CT; Harvard Medical School, Boston, Massachusetts, USA.; Division of Neuromuscular Medicine, Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA., Dubey D; Departments of Neurology and Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA., Gelfand JM; Department of Neurology, UCSF, San Francisco, California, USA., Guptill JT; Duke Clinical Research Institute, Duke University, Durham, NC, USA.; Division of Neuromuscular Medicine, Duke University, Durham, NC, USA., Johnson DB; Division of Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA., Juel VC; Division of Neuromuscular Medicine, Duke University, Durham, NC, USA., Kadish R; Department of Neurology, University of Utah, Salt Lake CIty, UT, USA., Kolb N; Division of Neuromuscular Medicine, Department of Neurology, University of Vermont, Burlington, VT, USA., LeBoeuf NR; Harvard Medical School, Boston, Massachusetts, USA.; Department of Dermatology, Center for Cutaneous Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA, USA., Linnoila J; Harvard Medical School, Boston, Massachusetts, USA.; Division of Neuroimmunology and Neuroinfectious Disease, Massachusetts General Hospital, Boston, Massachusetts, USA., Mammen AL; Muscle Disease Unit, Laboratory of Muscle Stem Cells and Gene Regulation, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA., Martinez-Lage M; Harvard Medical School, Boston, Massachusetts, USA.; Division of Neuropathology, Department of Pathology, Massachusetts General Hospital, Boston, MA, USA., Mooradian MJ; Harvard Medical School, Boston, Massachusetts, USA.; Division of Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA., Naidoo J; Medical Oncology, Department of Medicine, Beaumont Hospital Dublin and RCSI University of Health Sciences, Dublin, Ireland.; Upper Aerodigestive Division, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center/Johns Hopkins University, Baltimore, MD, USA., Neilan TG; Harvard Medical School, Boston, Massachusetts, USA.; Cardio-oncology Program, Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA., Reardon DA; Harvard Medical School, Boston, Massachusetts, USA.; Center for Neuro-oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Rubin KM; Harvard Medical School, Boston, Massachusetts, USA.; Division of Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA., Santomasso BD; Department of Neurology, Brain Tumor Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Sullivan RJ; Harvard Medical School, Boston, Massachusetts, USA.; Division of Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA., Wang N; Harvard Medical School, Boston, Massachusetts, USA.; Division of Neuro-Oncology, Department of Neurology, Massachusetts General Hospital, Boston, MA, USA., Woodman K; Section of Cancer Neurology, Department of Neuro-Oncology, MD Anderson Cancer Center, Houston, TX, USA., Zubiri L; Harvard Medical School, Boston, Massachusetts, USA.; Division of Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA., Louv WC; Project Data Sphere, Cary, North Carolina, USA., Reynolds KL; Harvard Medical School, Boston, Massachusetts, USA AGUIDON@PARTNERS.ORG kreynolds7@partners.org.; Division of Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.

Publikováno v: Journal for immunotherapy of cancer [J Immunother Cancer] 2021 Jul; Vol. 9 (7).